Trial Profile
A phase II trial of BL 8040 (BKT 140) for stem cell mobilisation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2013
Price :
$35
*
At a glance
- Drugs Motixafortide (Primary)
- Indications Multiple myeloma; Non-Hodgkin's lymphoma; Stem cell mobilisation
- Focus Therapeutic Use
- 17 Apr 2013 This study will commence shortly, according to a BioLineRx media release.
- 27 Aug 2010 New trial record